Skip to main content

Table 1 Sample characteristics before and after matching

From: Evaluation of disability in patients exposed to fluoroquinolones

CharacteristicBefore matchingAfter matching
NFQAZ/ST FQAZ/ST 
155,776294,663 119,653119,653 
 PercentStandardized DifferencePercentStandardized Difference
Age group
15–19000000
20–240.91−0.010.90.90
25–295.46.3−0.045.75.50.01
30–34910.8−0.069.49.10.01
35–3912.314−0.0512.612.30.01
40–4415.416.1−0.0215.515.20.01
45–4917.5170.0117.417.50
50–5418.3170.0418.118.4−0.01
55–5914.912.80.0614.414.9−0.01
60–646.24.90.065.96.2−0.01
65–690.100.010.10.10
Female gender59.149.30.25758.6−0.03
Medical history
Dysuria61.70.233.93.50.02
Hematuria syndrome3.20.90.161.91.70.01
Medication use
Phenazopyridine hydrochloride 200 mg oral tablet5.31.30.233.12.80.02
Nitrofurantoin, Macrocrystals 25 mg/ Nitrofurantoin, Monohydrate 75 mg oral capsule9.95.60.167.97.90
Amoxicillin 875 mg / Clavulanate 125 mg oral tablet9.24.90.177.68.1−0.02